Roshana Shrestha1, Samita Pant2, Ashis Shrestha2, Kabita Hada Batajoo3, Rashmi Thapa4, Sumana Vaidya2. 1. Department of General Practice and Emergency Medicine, Manmohan Medical College and Teaching Hospital, Swoyambhu, Kathmandu, Nepal. 2. Department of General Practice and Emergency Medicine, Patan Academy of Health Sciences, PAHS, Patan, Nepal. 3. Department of General Practice and Emergency Medicine, KIST Medical College Hospital, Patan, Nepal. 4. Department of General Practice and Emergency Medicine, KMC Medical College Hospital, Kathmandu, Nepal.
Abstract
BACKGROUND: Pain in the emergency department (ED) is common but undertreated. The objective of this study was to examine the efficacy and safety of intranasal (IN) ketamine used as an analgesic for patients with acute injury with moderate to severe pain. METHODS: This study was a cross sectional, observational study of patients more than 8 years old experiencing moderate to severe pain [visual analog score (VAS) >50 mm]. The initial dose of IN ketamine was 0.7 mg/kg with an additional dose of 0.3 mg/kg if VAS was more than 50 mm after 15 minutes. Pain scores and vital signs were recorded at 0, 15, 30 and 60 minutes. Side-effects, sedation level and patient's satisfaction were also recorded. The primary outcome was the number of patients achieving ≥ 20 mm reductions in VAS at 15 minutes. Other secondary outcome measures were median reduction in VAS at 15, 30 and 60 minutes, changes of vital signs, adverse events, satisfaction of patients, and need for additional ketamine. RESULTS: Thirty-four patients with a median age of 29.5 years (IQR 17.5-38) were enrolled, and they had an initial median VAS of 80 mm (IQR 67-90). The VAS decreased more than 20 mm at 15 minutes in 27 (80%) patients. The reduction of VAS from baseline to 40 mm (IQR 20-40), 20 mm (IQR 14-20) and 20 mm (IQR 10-20) respectively at 15, 30 and 60 minutes (P<0.001). No critical changes of vital signs were noted and adverse effects were mild and transient. CONCLUSION: This study showed that IN ketamine is an analgesic choice for patients with acute injury in moderate to severe pain in an overcrowded and resource limited ED.
BACKGROUND:Pain in the emergency department (ED) is common but undertreated. The objective of this study was to examine the efficacy and safety of intranasal (IN) ketamine used as an analgesic for patients with acute injury with moderate to severe pain. METHODS: This study was a cross sectional, observational study of patients more than 8 years old experiencing moderate to severe pain [visual analog score (VAS) >50 mm]. The initial dose of IN ketamine was 0.7 mg/kg with an additional dose of 0.3 mg/kg if VAS was more than 50 mm after 15 minutes. Pain scores and vital signs were recorded at 0, 15, 30 and 60 minutes. Side-effects, sedation level and patient's satisfaction were also recorded. The primary outcome was the number of patients achieving ≥ 20 mm reductions in VAS at 15 minutes. Other secondary outcome measures were median reduction in VAS at 15, 30 and 60 minutes, changes of vital signs, adverse events, satisfaction of patients, and need for additional ketamine. RESULTS: Thirty-four patients with a median age of 29.5 years (IQR 17.5-38) were enrolled, and they had an initial median VAS of 80 mm (IQR 67-90). The VAS decreased more than 20 mm at 15 minutes in 27 (80%) patients. The reduction of VAS from baseline to 40 mm (IQR 20-40), 20 mm (IQR 14-20) and 20 mm (IQR 10-20) respectively at 15, 30 and 60 minutes (P<0.001). No critical changes of vital signs were noted and adverse effects were mild and transient. CONCLUSION: This study showed that IN ketamine is an analgesic choice for patients with acute injury in moderate to severe pain in an overcrowded and resource limited ED.
Entities:
Keywords:
Analgesia; Intranasal; Ketamine; Pain; Visual analog score
Authors: Daniel B Carr; Leonidas C Goudas; William T Denman; Daniel Brookoff; Peter S Staats; Loralie Brennen; Geoff Green; Randi Albin; Douglas Hamilton; Mark C Rogers; Leonard Firestone; Philip T Lavin; Fred Mermelstein Journal: Pain Date: 2004-03 Impact factor: 6.961
Authors: Ulrika Espefält Westin; Emma Boström; Johan Gråsjö; Margareta Hammarlund-Udenaes; Erik Björk Journal: Pharm Res Date: 2006-02-25 Impact factor: 4.200
Authors: Daniel S Tsze; Dale W Steele; Jason T Machan; Fatemeh Akhlaghi; James G Linakis Journal: Pediatr Emerg Care Date: 2012-08 Impact factor: 1.454
Authors: Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal Journal: Expert Rev Clin Pharmacol Date: 2016-07-04 Impact factor: 5.045
Authors: Brian G Cornelius; Elizabeth Webb; Angela Cornelius; Kenneth W G Smith; Srdan Ristic; Jay Jain; Urska Cvek; Marjan Trutschl Journal: World J Emerg Med Date: 2018
Authors: Aurora J A E van de Loo; Adriana C Bervoets; Loes Mooren; Noor H Bouwmeester; Johan Garssen; Rob Zuiker; Guido van Amerongen; Joop van Gerven; Jaskaran Singh; Peter Van der Ark; Maggie Fedgchin; Randall Morrison; Ewa Wajs; Joris C Verster Journal: Psychopharmacology (Berl) Date: 2017-07-28 Impact factor: 4.530
Authors: Eric S Schwenk; Eugene R Viscusi; Asokumar Buvanendran; Robert W Hurley; Ajay D Wasan; Samer Narouze; Anuj Bhatia; Fred N Davis; William M Hooten; Steven P Cohen Journal: Reg Anesth Pain Med Date: 2018-07 Impact factor: 6.288
Authors: Mauricio Fernandes; Magdalena Schelotto; Philipp Maximilian Doldi; Giovanna Milani; Abul Andrés Ariza Manzano; Doriam Perera Valdivia; Alexandra Marie Winter Matos; Yasmin Hamdy Abdelrahim; Shaza Ahmed Hamad Bek; Benito K Benitez; Vanessa Luiza Romanelli Tavares; Abdulrahim M Basendwah; Luis Henrique Albuquerque Sousa; Naiara Faria Xavier; Tania Zertuche Maldonado; Sarah Toyomi de Oliveira; Melisa Chaker; Michelle Menon Miyake; Elif Uygur Kucukseymen; Kinza Waqar; Ola M J Alkhozondar; Ricardo Bernardo da Silva; Guilhermo Droppelmann; Antonio Vaz de Macedo; Rui Nakamura; Felipe Fregni Journal: F1000Res Date: 2021-01-22